Biomarkers and HPV testing: The future of cervical screening
|
|
- Lucy Robertson
- 5 years ago
- Views:
Transcription
1 THE FUTURE OF CERVICAL SCREENING Earn 3 CPD Points online Biomarkers and HPV testing: The future of cervical screening Professor John O Leary Associate Professor and Director of Pathology Coombe Women and Infants Hospital Trinity College, Dublin This presentation was made possible by an unrestricted educational grant from Roche Diagnostic, which had no control over content. SEPTEMBER
2 Earn 3 CPD points at Click on Accredited Education Programmes/CPD 2 SEPTEMBER 2014
3 SEPTEMBER
4 Earn 3 CPD points at Click on Accredited Education Programmes/CPD 4 SEPTEMBER 2014
5 The HPV negative woman SEPTEMBER
6 Earn 3 CPD points at Click on Accredited Education Programmes/CPD 6 SEPTEMBER 2014
7 SEPTEMBER
8 Earn 3 CPD points at Click on Accredited Education Programmes/CPD 8 SEPTEMBER 2014
9 SEPTEMBER
10 Earn 3 CPD points at Click on Accredited Education Programmes/CPD 10 SEPTEMBER 2014
11 SEPTEMBER
12 Earn 3 CPD points at Click on Accredited Education Programmes/CPD 12 SEPTEMBER 2014
13 SEPTEMBER
14 14 SEPTEMBER 2014 Biomarkers and HPV testing: The future of cervical screening
15 References 1. Rodriquez AC, Schiffman M, Herrero R et al. Longitudinal study of human Papillomavirus persistence and cervical intra-epithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102(5): Schiffman M, Wentzensen N. From human papillomarirus to cervical cancer. Obstetrics and Gynaecol 2010; 116(1): Meijer CJ, Berkhof H, Heideman DA, et al. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009, 46(Suppl 3): S Dillner J, Rebolj M, Birembaut P, Petry KU, et al. Long term predictive values of cytology and HPV testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a Wright TC Jr, Stoler MH, Behrens CM, et al. The ATHENA human Papillomavirus study: design, methods and baseline results. Am J Obstet Gynaecol 2012; 206(1): 46.e1-46.e11 6. Van Rosmalen J, de Kok IM, van Ballegooijen M. Cost effectiveness of cervical screening: cytology versus HPV DNA testing. BJOG 2012; 119(6): Dijkstra MG, Snijders PJ, Arbyn M, et al. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Onco 2014; 25(5): Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97(14): Cox JT, Castkle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013; 208(3):184. e1-184.e Rijkaart DC, Berkhof J, van Kemenade FJ, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012; 130(3): Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of highgrade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-ink4a results: a prospective analysis of a nested sub study of the NTCC randomised controlled trial. Lancet Oncol 2013; 14(2): Ikenberg H, Bergeron C, Schmidt D, et al. Screening for cervical cancer precursors with p16/ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 2013; 105(20): CPD How to earn CPD points: Visit click on Accredited Educational Programmes/CPD, click on registration, then answer the relevant questionnaire. Your CPD certificate will be ed to you within a week. Disclaimer The views and opinions expressed in the article are those of the presenters and do not necessarily reflect those of the publisher or its sponsor. In all clinical instances, medical practitioners are referred to the product insert documentation as approved by relevant control authorities. Published by 70 Arlington Street, Everglen, Cape Town, 7550 Tel: (021) I info@denovomedica.com SEPTEMBER
The devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationChapter 5. M.G. Dijkstra L. Rozendaal M. van Zummeren F.J. van Kemenade P.J.F. Snijders C.J.L.M. Meijer J. Berkhof. Submitted for publication
Chapter 5 CIN3 and cancer risks after primary HPV DNA testing and cytology triage in cervical cancer screening: fifteen years follow-up of a randomized controlled trial M.G. Dijkstra L. Rozendaal M. van
More informationEvidence-based treatment of a positive HPV DNA test. Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR
Evidence-based treatment of a positive HPV DNA test Th. Agorastos Prof. of Obstetrics & Gynaecology Aristotle University Thessaloniki/GR HPV DNA testing Indications 1. Triage after cytology with ASCUS/LSIL
More informationCINtec PLUS and the Pap smear: a co-testing alternative
CINtec PLUS and the Pap smear: a co-testing alternative Rosemary Tambouret MD p16/ki67 (CINtec PLUS) and the Pap smear Rosemary Tambouret MD CINtec PLUS dual stain: p16 and Ki67 p16 is anti-proliferative
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationP16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future. Mark H Stoler, MD University of Virginia Health System, Charlottesville, VA,
More informationCervical cancer prevention: Advances in primary screening and triage system
Cervical cancer prevention: Advances in primary screening and triage system Dr Farid Hadi Regional Medical and Scientific Affairs Roche Diagnostics Asia-Pacific, Singapore Cervical cancer is highly preventable
More informationChapter 4. Triaging HPV-positive women with normal cytology by p16/ki-67 dual-stained cytology testing: Baseline and longitudinal data
Chapter 4 Triaging HPV-positive women with normal cytology by p16/ki-67 dual-stained cytology testing: Baseline and longitudinal data Margot H. Uijterwaal Nicole J. Polman Birgit I. Witte Folkert J. Van
More informationChapter 2. Br J Cancer Mar 18;110(6):
Chapter 2 Triaging borderline/mild dyskaryotic Pap cytology with p16/ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study Margot H. Uijterwaal Birgit I. Witte Folkert J.
More informationCervical-Cancer Screening with Human Papillomavirus and Cytologic Cotesting
The new england journal of medicine clinical practice Caren G. Solomon, M.D., M.P.H., Editor Cervical-Cancer Screening with Human Papillomavirus and Cytologic Cotesting Mark Schiffman, M.D., M.P.H., and
More informationThe clearest path to the most meaningful results. The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way
The clearest path to the most meaningful results The cobas HPV Test delivers clinical value with workflow efficiencies every step of the way The cobas HPV Test KNOW THE RISK Help guide clinical decision
More informationScreening for Cervical Cancer. Grand Rounds 1/16/13 Meggan Linck
Screening for Cervical Cancer Grand Rounds 1/16/13 Meggan Linck Cervical Cancer Worldwide 2 nd most common and 5 th deadliest U.S. 8 th most common 80% occur in developing world Median age at diagnosis
More informationHPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe. Mark H. Stoler, MD ASC Companion Meeting USCAP 2008
OBJECTIVES: HPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe Mark H. Stoler, MD ASC Companion Meeting USCAP 2008 1. Describe the concept of marker validation in the context of HPV tests. 2. Present
More informationTriaging borderline/mild dyskaryotic Pap cytology with p16/ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study
FULL PAPER British Journal of Cancer (2014) 110, 1579 1586 doi: 10.1038/bjc.2014.34 Keywords: HPV; cervical intraepithelial neoplasia; borderline/mildly dyskaryotic cytology; p16/ki-67 dual-stained cytology
More informationTHE NEW ERA OF PRIMARY HPV SCREENING FOR PREVENTION OF INVASIVE CERVICAL CANCER
THE NEW ERA OF PRIMARY HPV SCREENING FOR PREVENTION OF INVASIVE CERVICAL CANCER Philip E Castle 1,2 1. Cancer Modelling Group, Lowy Cancer Research Centre, University of New South Wales, Australia. 2.
More informationHPV Molecular Diagnostics and Cervical Cytology. Philip E. Castle, PhD, MPH American Society for Clinical Pathology (ASCP) March 15, 2012
HPV Molecular Diagnostics and Cervical Cytology Philip E. Castle, PhD, MPH American Society for Clinical Pathology (ASCP) March 15, 2012 Disclosures & Disclaimers I serve on a Merck Data and Safety Monitoring
More informationUsefulness of p16/ki67 Immunostaining in the Triage of Women Referred to Colposcopy
Usefulness of p16/ki67 Immunostaining in the Triage of Women Referred to Colposcopy Jaume Ordi, MD, PhD 1 ; Amaia Sagasta, MD 1 ; Meritxell Munmany, MD 2 ; Leonardo Rodrıguez-Carunchio, MD 1 ; Aureli Torne,
More informationThe implications of HPV immunisation on cervical screening
The implications of HPV immunisation on cervical screening Dr Maggie Cruickshank Senior Lecturer in Gynaecology Scottish Cervical Cancer Prevention Programme (SCCPP) funded by CSO Cervical screening Detects
More information32 OBG Management May 2015 Vol. 27 No. 5 obgmanagement.com
The Advisory Committee on Immunization Practices recommends routine vaccination against HPV in 11- and 12-year-olds, although the age can range from 9 to 26 years (for those who have not been vaccinated
More informationHUMAN PAPILLOMAVIRUS TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018
More informationThe data from the ATHENA study and others bring this expectation and the appropriateness of the guidelines for women aged into question.
New data support HPV testing beginning at age 25 By Hope Cottrill, M.D. Recent findings from the ATHENA (Addressing the Need for Advanced HPV Diagnostics) study of cervical cancer screening revealed surprising
More informationGynecologic Oncology
Gynecologic Oncology 121 (2011) 505 509 Contents lists available at ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno Triaging Pap cytology negative, HPV positive cervical
More informationRESEARCH. open access
open access Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised
More informationp16/ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population
CHAPTER 3 p16/ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population Roosmarijn Luttmer Maaike G. Dijkstra Peter J.F. Snijders Johannes Berkhof
More informationcolds and flu Introduction KEY MESSAGES
colds and flu New insights: Cold and flu Introduction Colds and flu are responsible for more visits to the pharmacy than any other infectious illness. While severity of influenza differs from year to year,
More informationNew Strategies for HPV-based Cervical Screening
New Strategies for HPV-based Cervical Screening Prof Attila Lorincz, Dr Alejandra Castanon, Dr Anita Wey Wey Lim, Prof Peter Sasieni Centre for cancer Prevention, Wolfson Institute of Preventive Medicine,
More informationXinxin Du, Shufang Jiang, Aijun Liu, Yurong Fu, Yun Zhang, Yuanguang Meng *
Biomedical Research 2018; 29 (1): 203-208 ISSN 0970-938X www.biomedres.info Comparison of HPV testing by real-time fluorescent PCR and hc2 for detection of high-grade cervical intraepithelial neoplasia
More informationAmbulatory blood pressure monitoring is key to improving hypertension diagnosis
Earn 2 CEU Points online Ambulatory blood pressure monitoring is key to improving hypertension diagnosis Professor Bryan Williams Director of the UCL Biomedical Research Centre University College London
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationCytology history preceding cervical cancer diagnosis: a regional analysis of 286 cases
British Journal of Cancer (2011) 104, 685 692 All rights reserved 0007 0920/11 www.bjcancer.com Cytology history preceding cervical cancer diagnosis: a regional analysis of 286 cases MGök 1, L Rozendaal
More informationMolecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution. Mark H. Stoler, MD PSC Symposium USCAP 2008
Molecular Analysis in the Diagnosis and Management of Lesions of Uterine Cervix: The 95% solution Mark H. Stoler, MD PSC Symposium USCAP 2008 Objectives: This presentation will briefly review the currently
More informationEmerging Challenges in Primary Care. Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing
Emerging Challenges in Primary Care Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause Practitioner
More informationChapter 2. Journal of Clinical Virology 2012; 2:
Chapter 2 Brush-based self-sampling in combination with GP5+/6+-PCR-based hrhpv testing: high concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN M.G. Dijkstra
More informationCan HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
More informationJournal of Clinical Virology
Journal of Clinical Virology 54 (2012) 147 151 Contents lists available at SciVerse ScienceDirect Journal of Clinical Virology j ourna l ho mepage: www.elsevier.com/locate/jcv Brush-based self-sampling
More informationCervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients Richard Hopley, MD, Alexandra Gillespie, MD* Laboratory Medicine 47:1:52-56 CLINICAL HISTORY Patients:
More informationMolecular Triage: Partial and Extended Genotyping and More!
Molecular Triage: Partial and Extended Genotyping and More! Thomas C. Wright, Jr. MD Professor Emeritus Columbia University, New York Pathologist, Enzo Clinical Laboratories, Farmingdale, NY Disclosures
More informationThe Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationHuman Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of
JCM Accepts, published online ahead of print on 1 February 2012 J. Clin. Microbiol. doi:10.1128/jcm.06656-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 Human Papillomavirus
More informationOriginal Articles. Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests?
Original Articles Do Infection Patterns of Human Papillomavirus Affect the Cytologic Detection of High-Grade Cervical Lesions on Papanicolaou Tests? Siavash Azadmanesh Samimi, MD; Roxanne R. Mody, MD;
More informationpremix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence
Earn 3 CPD Points online Using a premix insulin (BIAsp 30) with a DPP-4 inhibitor what are the facts? New Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30)
More informationCHAPTER 4. International Journal of Cancer 2015; 138:
CHAPTER 4 Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient
More informationIJC International Journal of Cancer
IJC International Journal of Cancer The clinical impact of using p16 INK4a immunochemistry in cervical histopathology and cytology: An update of recent developments Christine Bergeron 1, Guglielmo Ronco
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6857 Cost-Effectiveness of Strategies for Detection CIN2+ in Women with ASC-US Pap Smears in Thailand RESEARCH ARTICLE Cost-Effectiveness Analysis of Different
More informationHPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{epb41l3} methylation classifier.
HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and \textit{epb41l3} methylation classifier. Brentnall, AR; Vasiljevic, N; Scibior-Bentkowska, D;
More informationGoals. In the News. Primary HPV Screening 3/9/2015. Your PAP and HPV Update Primary HPV Testing- Screening Intervals- HPV Vaccine Updates-
Your PAP and HPV Update 2015 Connie Mao, MD University of Washington Goals Primary HPV Testing- Is it time to stop doing pap smears? Screening Intervals- Should patients have a choice? HPV Vaccine Updates-
More informationChapter 6. Submitted for publication
Chapter 6 CADM1 and MAL promoter methylation levels in hrhpv-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease Submitted for publication Mariska Bierkens
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More informationChapter 6. * both authors contributed equally. International Journal of Cancer 2015; doi: /ijc.29824
Chapter 6 Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynaecologic outpatient
More informationEdinburgh Research Explorer
Edinburgh Research Explorer Long-term follow-up of cervical disease in women screened by cytology and HPV testing Citation for published version: Mesher, D, Szarewski, A, Cadman, L, Cubie, H, Kitchener,
More informationHPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening in Chile
Lagos et al. Infectious Agents and Cancer (2015) 10:43 DOI 10.1186/s13027-015-0038-5 RESEARCH ARTICLE Open Access HPV16/18 genotyping for the triage of HPV positive women in primary cervical cancer screening
More informationCOMPARISON OF HPV AND CYTOLOGY TRIAGE ALGORITHMS FOR WOMEN WITH BORDERLINE OR MILD DYSKARYOSIS IN POPULATION-BASED SCREENING (VUSA-SCREEN TRIAL)
2 Dorien C. Rijkaart Johannes Berkhof Folkert J. Van Kemenade Lawrence Rozendaal Rene H.M. Verheijen Saskia Bulk COMPARISON OF HPV AND CYTOLOGY TRIAGE ALGORITHMS FOR WOMEN WITH BORDERLINE OR MILD DYSKARYOSIS
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Comparing the performance of FAM19A4 methylation analysis, cytology and for the detection of cervical (pre)cancer in high-risk HPV-positive women of a gynecologic outpatient
More informationJean-Christophe Noël and Philippe Simon. 1. Introduction
Analytical Cellular Pathology Volume 2015, Article ID 746502, 4 pages http://dx.doi.org/10.1155/2015/746502 Research Article Limitations on the Detection Rate of High-Risk HPV by Hybrid Capture 2 Methodology
More informationBeyond Pap Morphological Triage: p16/ki67 Dual Staining
Moving away from Beyond Pap Morphological Triage: p16/ki67 Dual Staining Nicolas Wentzensen MD, PhD, MS Deputy Chief, Clinical Genetics Branch; Head, Clinical Epidemiology Unit National Cancer Institute
More informationABSTRACT INTRODUCTION
/, 2017, Vol. 8, (No. 48), pp: 83890-83899 A cocktail of p16 INK4a and Ki-67, p16 INK4a and minichromosome maintenance protein 2 as triage tests for human papillomavirus primary cervical cancer screening
More informationNIH Public Access Author Manuscript Lancet Oncol. Author manuscript; available in PMC 2012 February 6.
NIH Public Access Author Manuscript Published in final edited form as: Lancet Oncol. 2011 July ; 12(7): 663 672. doi:10.1016/s1470-2045(11)70145-0. Cervical Cancer Risk for 330,000 Women Undergoing Concurrent
More informationSupplements to the European Guidelines on Prevention of Cervical Cancer
Asturias, 23 October, 2011 Asturias, 23 October Supplements to the European Guidelines on Prevention of Cervical Cancer M. Arbyn Unit Cancer Epidemiology, IPH, Brussels, Belgium Rue Juliette Wytsmanstraat
More informationManagement of high-risk HPV-positive women for detection of cervical (pre)cancer
Expert Review of Molecular Diagnostics ISSN: 1473-7159 (Print) 1744-8352 (Online) Journal homepage: http://www.tandfonline.com/loi/iero20 Management of high-risk HPV-positive women for detection of cervical
More informationManagement of high-risk HPV-positive women for detection of cervical (pre)cancer
Expert Review of Molecular Diagnostics ISSN: 1473-7159 (Print) 1744-8352 (Online) Journal homepage: http://www.tandfonline.com/loi/iero20 Management of high-risk HPV-positive women for detection of cervical
More informationDisclosures & images
Cervical Cancer Screening: New Approaches Levi S. Downs, Jr., MD Disclosures & images During the previous 12 months, I have been a consultant for and received honoraria from Merck. Images are attributed
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice Nicolas Wentzensen 1, Marc Arbyn 2, Johannes Berkhof 3, Mark Bower 4, Karen Canfell 5, Mark Einstein
More informationChallenges in type 2 diabetes control: slipping control and weight gain
control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists
More informationHPV Primary Screening in the United States
IFCPC 15th World Congress May 2014, London, UK. HPV Primary Screening in the United States E.J. Mayeaux, Jr., M.D. Professor and Chairman Department of Family and Preventive Medicine Professor of Obstetrics
More informationp16/ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China
/, Vol. 7, No. 40 p16/ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China Lu-Lu Yu 1, Hui-Qin Guo 2, Xiao-Qin Lei 1, Yu
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Effectiveness of novel, lower cost molecular human papillomavirus-based tests for cervical cancer screening in rural china Melissa Valdez 1, Jose Jeronimo 1, Pooja Bansil
More informationUniversal human papillomavirus genotyping by the digene. HPV Genotyping RH and LQ Tests
CHAPTER 5 Universal human papillomavirus genotyping by the digene HPV Genotyping RH and LQ Tests Daan T. Geraets, Charlotte H. Lenselink, Ruud L.M. Bekkers, Leen-Jan van Doorn, Wim G.V. Quint, Willem J.G.
More informationUniversity of Groningen. New insights in methodology of screening for cervical cancer Wang, Rong
University of Groningen New insights in methodology of screening for cervical cancer Wang, Rong IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationComparison of an optoelectronic scan of the cervix, cervical cytology and HPV genotyping for CIN screening
Comparison of an optoelectronic scan of the cervix, cervical cytology and HPV genotyping for CIN screening Ricardo Lúa Alvarado President of Occident Colposcopy and Genital Pathology College Professor
More informationSince the 1960s, colposcopy of the cervix with
Original Research Relevance of Random Biopsy at the Transformation Zone When Colposcopy Is Negative Warner K. Huh, MD, Mario Sideri, MD, Mark Stoler, MD, Guili Zhang, PhD, Robert Feldman, MD, and Catherine
More informationUpdate on HPV Testing. Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories
Update on HPV Testing Robert Schlaberg, M.D., Dr. med., M.P.H. Assistant Professor, University of Utah Medical Director, ARUP Laboratories Disclosures In accordance with ACCME guidelines, any individual
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationA Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,
Correlation Between Hybrid Capture II High-Risk Human Papillomavirus DNA Test Chemiluminescence Intensity From Cervical Samples With Follow-Up Histologic Results A Cytologic/Histologic Review of 367 Cases
More informationAjmal Akbari 1, Davy Vanden Broeck 1,2,3,4*, Ina Benoy 1,2,4, Elizaveta Padalko 2,5, Johannes Bogers 1,2,3,4 and Marc Arbyn 6
Akbari et al. Virology Journal (2018) 15:166 https://doi.org/10.1186/s12985-018-1076-6 RESEARCH Validation of intra- and inter-laboratory reproducibility of the Xpert HPV assay according to the international
More informationPunch biopsies shorten time to clearance of high-risk human papillomavirus infections of the uterine cervix
Petry et al. BMC Cancer (2018) 18:318 https://doi.org/10.1186/s12885-018-4225-9 RESEARCH ARTICLE Punch biopsies shorten time to clearance of high-risk human papillomavirus infections of the uterine cervix
More informationChanges in type-specific human papillomavirus load predict progression to cervical cancer
J. Cell. Mol. Med. Vol 16, No 12, 2012 pp. 3096-3104 Changes in type-specific human papillomavirus load predict progression to cervical cancer Christophe E. Depuydt a, *, Arnold M. Criel a, Ina H. Benoy
More informationA second generation cervico-vaginal lavage device shows similar performance as its preceding version with respect to DNA yield and HPV DNA results
Verhoef et al. BMC Women's Health 2013, 13:21 RESEARCH ARTICLE Open Access A second generation cervico-vaginal lavage shows similar performance as its preceding version with respect to DNA yield and HPV
More informationIJC International Journal of Cancer
IJC International Journal of Cancer Reliable identification of women with N3+ using hrhpv genotyping and methylation markers in a cytology-screened referral population Annemiek Leeman 1, Marta del Pino
More informationScreening for Cervical Cancer Reference List
SEER Cancer Statistics Factsheets: Cervix Uteri Cancer. [cited May 12, 2016]; Available from: http://seer.cancer.gov/statfacts/html/cervix.html Healthy People 2020. [cited May 12, 2016]; Available from:
More informationDisclosures. Goal of Cervical Cancer Screening. Update on Cervical Cancer Screening: Appropriate Use of Pap and HPV Testing
Disclosures Update on Cervical Cancer Screening: Appropriate Use of Pap and HPV Testing Consultant and Speaker: Hologic Nancy R. Berman MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner/Colposcopist Certified
More informationAbnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology,
More informationNews from IPVS - October 2016
View this email in your browser News from IPVS - October 2016 Silvia de Sanjosé, MD, PhD IPVS President Barcelona, 25th October 2016 Dear IPVS Members, We have now finalized our programme for the upcoming
More informationComparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme
To cite: Nygård M, Røysland K, Campbell S, et al. Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme. BMJ Open 2013;4:e003460. doi:10.1136/bmjopen-2013-003460
More informationASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
More informationSESSION J4. What's Next? Managing Abnormal PAPs in 2014
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION J4 What's Next? Managing Abnormal PAPs in 2014 Session Description: Linda Eckert, MD Review current guidelines
More informationEvaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology- Negative Results
Anatomic Pathology / HPV DNA Testing in Women With Negative Cytology Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology- Negative Results Thomas C. Wright Jr,
More informationMTC - MAIN TRAINING COURSE
PRELIMINARY PROGRAM OF MAIN CONGRE AS OF MAY 14, 2018 Dates and timing details of sessions are subject to change MTC - MAIN TRAINING COURSE SUNDAY, DEC 2 MTC 1 HPV induced cancers: rapid changes in epidemiology,
More informationHPV test results and histological follow-up results of patients with LSIL Cervical Cytology from the Largest CAP-certified laboratory in China
2436 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(13): 2436-2441. doi: 10.7150/jca.19421 HPV test results and histological follow-up results of patients with LSIL Cervical
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 13: , 2017
3032 Clinical progress of human papillomavirus genotypes and their persistent infection in subjects with atypical squamous cells of undetermined significance cytology: Statistical and latent Dirichlet
More informationPrior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory
Prior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory Baowen Zheng, MD 1 ; Zaibo Li, MD, PhD 2 ; Christopher C. Griffith, MD, PhD
More information9/19/17. Emerging Challenges in Primary Care: Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing. Faculty.
Emerging Challenges in Primary Care: 2017 Cervical Cancer Screening: Appropriate Use of Pap & HPV Testing Faculty Nancy R. Berman, MSN, ANP-BC, NCMP, FAANP Adult Nurse Practitioner Certified Menopause
More informationThe Interplay of Age Stratification and HPV Testing on the Predictive Value of ASC-US Cytology Results From the ATHENA HPV Study
Anatomic Pathology / Age and HPV Testing in Women With ASC-US The Interplay of Age Stratification and HPV Testing on the Predictive Value of ASC-US Cytology Results From the ATHENA HPV Study Mark H. Stoler,
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationMEDICAL POLICY I. POLICY
Original Issue Date (Created): July 1, 2002 Most Recent Review Date (Revised): September 25, 2012 Effective Date: October 1, 2012 I. POLICY Cervicography Cervicography is considered investigational, as
More informationPromoting Cervical Screening Information for Health Professionals. Cervical Cancer
Promoting Cervical Screening Information for Health Professionals Cervical Cancer PapScreen Victoria Cancer Council Victoria 1 Rathdowne St Carlton VIC 3053 Telephone: (03) 635 5147 Fax: (03) 9635 5360
More informationHuman papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Human papillomavirus testing as a cytology gold standard: comparing Surinam with the Netherlands Mitchell S Wachtel 1,
More information